Moving to tolerance: Clinical application of T regulatory cells

Seminars in Immunology

Volumn 23, Issue 4, 2011, Pages 304-313

  McMurchy, Alicia N ^a,b   Bushell, Andrew ^c   Levings, Megan K ^a,b   Wood, Kathryn J ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cellular therapy; Drug minimization; T regulatory cells; Translational medicine; Transplantation

Indexed keywords

ALEMTUZUMAB; ANTIMITOTIC AGENT; CD3 ANTIBODY; CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; APOPTOSIS; CARDIAC GRAFT REJECTION; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CELL THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION;

ANIMALS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; EUROPE; GRAFT REJECTION; HUMANS; IMMUNOMODULATION; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TISSUE THERAPY; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 80955181118     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.04.001     Document Type: Review

References (142)

1. Reibke R., Garbi N., Ganss R., Hämmerling G.J., Arnold B., Oelert T. CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen. Proc Natl Acad Sci USA 2006, 103:15142-15147.
2. Zhang L., Bertucci A.M., Ramsey-Goldman R., Burt R.K., Datta S.K. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-β-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009, 183:6346-6358.
3. Li X.L., Ménoret S., Bezie S., Caron L., Chabannes D., Hill M., et al. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. J Immunol 2010, 185:823-833.
4. Zhang Z.-X., Yang L., Young K.J., Du Temple B., Zhang L. Identification of a previously unknown antigen specific regulatory T cell and its mechanism of suppression. Nat Med 2000, 6:782-789.
5. Ford McIntyre M.S., Young K.J., Gao J., Joe B., Zhang L. Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J Immunol 2008, 181:2271-2275.
6. Monteiro M., Almeida C.F., Caridade M., Ribot J.C., Duarte J., Agua-Doce A., et al. Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-beta. J Immunol 2010, 185:2157-2163.
7. Hayday A., Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. Nat Rev Immunol 2003, 3:233-242.
8. Andersson J., Tran D.Q., Pesu M., Davidson T.S., Ramsey H., O'Shea J.J., et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008, 205:1975-1981.
9. Thornton A.M., Korty P.E., Tran D.Q., Wohlfert E.A., Murray P.E., Belkaid Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010, 184:3433-3441.
10. Bennett C.L., Christie J.D., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
11. Kobayashi I., Shiari R., Yamada M., Kawamura N., Okano M., Yara A., et al. Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). J Med Genet 2001, 38:874-876.
12. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006, 116:1713-1722.
13. Lahl K., Loddenkemper C., Drouin C., Freyer J., Arnason J., Eberl G., et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007, 204:57-63.
14. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2006, 8:191-197.
15. Hall B.M., Jelbart M.E., Dorsch S.E. Suppressor T cells in rats with prolonged cardiac allograft survival after treatment with cyclosporin. Transplantation 1984, 37:595-600.
16. Hall B.M., Jelbart M.E., Gurley K.E., Dorsch S.E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med 1985, 162:1683-1694.
17. Hall B.M., Gurley K.E., Pearce N.W., Dorsch S.E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporin. II. Sequential changes in alloreactivity of T cell subsets. Transplantation 1989, 47:1030-1033.
18. Hall B., Pearce N., Gurley K., Dorsch S. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanism of action. J Exp Med 1990, 171:141-157.
19. Quigley R.L., Wood K.J., Morris P.J. Transfusion induces blood donor-specific suppressor cells. J Immunol 1989, 142:463-470.
20. +) T cell. Transplantation 1989, 47:684-688.
21. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A., et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001, 166:3789-3796.
22. Saitovitch D., Bushell A., Mabbs D.W., Morris P.J., Wood K.J. Kinetics of induction of transplantation tolerance with a nondepleting anti-CD4 monoclonal antibody and donor specific transfusion before transplantation: a critical period of time is required for development of immunological unresponsiveness. Transplantation 1996, 61:1642-1647.
23. Kingsley C.I., Karim M., Bushell A.R., Wood K.J. CD25+ CD4+ regulatory T cells prevent graft rejection: CTLA-4 and IL-10 dependent immunoregulation of alloresponses. J Immunol 2002, 168:1080-1086.
24. Bushell A., Wood K.J. GITR ligation blocks allograft protection by induced CD25+CD4+ regulatory T cells without enhancing effector T-cell function. Am J Trans 2007, 7:759-768.
25. Qin S., Cobbold S.P., Pope H., Elliot J., Kiossis D., Davies J., et al. " Infectious" transplantation tolerance. Science 1993, 259:974-977.
26. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
27. Morgan M.E., van Bilsen J.H., Bakker A.M., Heemskerk B., Schilham M.W., Hartgers F.C., et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005, 66:13-20.
28. Tran D.Q., Ramsey H., Shevach E.M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983-2990.
29. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
30. Gavin M.A., Torgerson T.R., Houston E., DeRoos P., Ho W.Y., Stray-Pedersen A., et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006, 103:6659-6664.
31. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
32. Cosimi A.B., Burton R.C., Colvin R.B., Goldstein G., Delmonico F.L., LaQuaglia M.P., et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981, 32:535-539.
33. Nooij F.J., Jonker M. The effect of skin allograft survival of a monoclonal antibody specific for a polymorphic CD3-like cell surface molecule in rhesus monkeys. Eur J Immunol 1987, 17:1089-1093.
34. Nicolls M.R., Aversa G.G., Pearce N.W., Spinelli A., Berger M.F., Gurley K.E., et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993, 55:459-468.
35. Knechtle S.J., Vargo D., Fechner J., Zhai Y., Wang J., Hanaway M.J., et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997, 63:1-6.
36. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994, 91:123-127.
37. Chatenoud L. CD3-specific antibody induced active tolerance: from bench to bedside. Nat Rev Immunol 2003, 3:123-132.
38. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7:622-632.
39. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
40. Minamimura K., Gao W., Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006, 176:4125-4132.
41. Gurkan S., Luan Y., Dhillon N., Allam S.R., Montague T., Bromberg J.S., et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010, 10:2132-2141.
42. Sewgobind V.D., Kho M.M., van der Laan L.J., Hendrikx T.K., van Dam T., Tilanus H.W., et al. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 2009, 24:1635-1644.
43. Broady R., Yu J., Levings M.K. ATG-induced expression of FOXP3 in human CD4+ T cells in vitro is associated with T-cell activation and not the induction of FOXP3+ T regulatory cells. Blood 2009, 114:5003-5006.
44. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002, 19:S3-S9.
45. Bloom D.D., Chang Z., Fechner J.H., Dar W., Polster S.P., Pascual J., et al. CD4+CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with campath-1H. Am J Transplant 2008, 8:793-802.
46. Battaglia M., Stabilini A., Roncarolo M.-G. Rapamycin selectively expands CD4+CD25+Foxp3+ regulatory T cells. Blood 2005, 105:4743-4748.
47. Pearl J.P., Parris J., Hale D.A., Hoffmann S.C., Bernstein W.B., McCoy K.L., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005, 5:465-474.
48. Adkins D., Ratanatharathorn V., Yang H., White B. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. Transplantation 2009, 88:198-202.
49. Shaffer J., Villard J., Means T.K., Alexander S., Dombkowski D., Dey B.R., et al. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol 2007, 35:1140-1152.
50. Andreola G, Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, et al. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant, in press.
51. Crellin N.K., Garcia R.V., Levings M.K. Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 2007, 109:2014-2022.
52. Valmori D., Tosello V., Souleimanian N.E., Godefroy E., Scotto L., Wang Y., et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006, 177:944-949.
53. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006, 177:8338-8347.
54. Strauss L., Whiteside T.L., Knights A., Bergmann C., Knuth A., Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007, 178:320-329.
55. San Segundo D., Carlos Ruiz J., Izquierdo M., Fernández-Fresnedo G., Gómez-Alamillo G., Merino R., et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006, 82:550-557.
56. Noris M., Casiraghi F., Todeschini M., Cravedi P., Cugini D., Monteferrante G., et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007, 18:1007-1018.
57. Bestard O., Cruzado J.M., Mestre M., Caldés A., Bas J., Carrera M., et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007, 179:4901-4909.
58. Monti P., Scirpoli M., Maffi P., Piemonti L., Secchi A., Bonifacio E., et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008, 57:2341-2347.
59. Zeiser R., Nguyen V.H., Beilhack A., Buess M., Schulz S., Baker J., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
60. Gao W., Lua Y., El Essawy B., Oukka M., Kuchroo V.J., Strom T.B. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7:1722-1732.
61. Hoffmann P., Eder R., Boeld T.J., Doser K., Piseshka B., Andreesen R., et al. Only the CD45RA+ subpopulation of CD4+CD25 high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006, 108:4260-4267.
62. Liu W., Putnam A.L., Xu-yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006, 203:1701-1711.
63. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
64. Miyara M., Yoshioka Y., Kitoh A., Shima T., Wing K., Niwa A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
65. Hoffmann P., Boeld T.J., Eder R., Huehn J., Floess S., Wieczorek G., et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009, 39:1088-1097.
66. Putnam A.L., Brusko T.M., Lee M.R., Liu W., Szot G.L., Ghosh T., et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009, 58:652-662.
67. Seddiki N., Santner-Nanan B., Tangye S.G., Alexander S.I., Solomon M., Lee S., et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006, 107:2830-2838.
68. Valmori D., Merlo A., Souleimanian N.E., Hesdorffer C.S., Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005, 115:1953-1962.
69. Tran D.Q., Andersson J., Hardwick D., Bebris L., Illei G.G., Shevach E.M. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5125-5133.
70. Dwyer K.M., Hanidziar D., Putheti P., Hill P.A., Pommey S., McRae J.L., et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010, 10:2410-2420.
71. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
72. Fletcher J.M., Lonergan R., Costelloe L., Kinsella K., Moran B., O'Farrelly C., et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009, 183:7602-7610.
73. Wang R., Kozhaya L., Mercer F., Khaitan A., Fujii H., Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009, 106:13439-13444.
74. Stockis J., Colau D., Coulie P.G., Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009, 39:3315-3322.
75. Tran D.Q., Andersson J., Wang R., Ramsey H., Unutmaz D., Shevach E.M. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009, 106:13445-13450.
76. Ito T., Hanabuchi S., Wang Y.H., Park W.R., Arima K., Bover L., et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
77. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
78. Earle K.E., Tang Q., Zhou X., Liu W., Zhu S., Bonyhadi M.L., et al. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol 2005, 115:3-9.
79. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003, 171:3348-3352.
80. Golovina T.N., Mikheeva T., Suhoski M.M., Aqui N.A., Tai V.C., Shan X., et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008, 181:2855-2868.
81. Thornton A.M., Donovan E.E., Piccirillo C.A., Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004, 172:6519-6523.
82. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 2004, 172:3983-3988.
83. Basu S., Golovina T., Mikheeva T., June C.H., Riley J.L. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008, 180:5794-5798.
84. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2010, [pre-published online October 15th 2010].
85. Macchiarini F., Manz M.G., Palucka A.K., Shultzabcd L.D. Humanized mice are we there yet?. J Exp Med 2005, 202:1307-1311.
86. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130.
87. Nadig S.N., Wieckiewicz J., Wu D.C., Warnecke G., Zhang W., Schiopu A., et al. In vivo prevention of transplant arteriosclerosis by ex vivo expanded human regulatory T cells. Nat Med 2010, 16:809-814.
88. Issa F., Hester J., Goto R., Nadig S.N., Goodacre T.E., Wood K.J. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010, 90:1321-1327.
89. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994, 179:589-600.
90. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
91. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270:985-988.
92. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus host disease lethality. Blood 2002, 99:3493-3499.
93. Zheng S.G., Gray J.D., Ohtsuka K., Yamagiwa S., Horwitz D.A. Generation ex-vivo of TGF-b-producing regulatory T cells from CD4+ CD25- precursors. J Immunol Methods 2002, 169:4183-4189.
94. Chen W., Jin W., Hardegan N., Lei K., Li L., Marinos N., et al. Conversion of peripheral CD4+ CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
95. Feng G., Gao W., Strom T.B., Oukka M., Francis R., Wood K.J., et al. Exogenous IFN-g ex-vivo shapes the alloreactive T cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 2008, 38:2512-2527.
96. + regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation 2008, 86:578-589.
97. Warnecke G., Feng G., Goto R., Nadig S.N., Francis R., Wood K.J., et al. CD4+ regulatory T cells generated in vitro with IFN-g and allogeneic APC inhibit transplant arteriosclerosis. Am J Pathol 2010, 177:464-472.
98. Zheng S.G., Meng L., Wang J.H., Watanabe M., Barr M.L., Cramer D.V., et al. Transfer of regulatory cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+CD25+ cells in the recipient. Int Immunol 2006, 18:279-289.
99. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
100. Battaglia M., Stabilini A., Draghici E., Gregori S., Mocchetti C., Bonifacio E., et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006, 55:40-49.
101. Zeller J.C., Panoskaltsis-Mortari A., Murphy W.J., Ruscetti F.W., Narula S., Roncarolo M.G., et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999, 163:3684-3691.
102. Bacchetta R., Gregori S., Serafini G., Sartirana C., Schulz U., Zino E., et al. Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica 2010, 95:2134-2143.
103. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.-Y., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
104. Khattri R., Cox T., Yasayko S.-A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
105. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcripition factor Foxp3. Science 2003, 299:1057-1061.
106. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
107. Chai J.G., Xue S.A., Coe D., Addey C., Bartok I., Scott D., et al. Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 2005, 79:1310-1316.
108. Allan S.E., Alstad A.N., Merindol N., Crellin N.K., Amendola M., Bacchetta R., et al. Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 2008, 16:194-202.
109. Allan S.E., Song-Zhao G.X., Abraham T., McMurchy A.N., Levings M.K. Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 2008, 38:3282-3289.
110. Tsang J., Tanriver Y., Jiang S., Xue S., Ratnasothy K., Chen D., et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2009, 118:3619-3628.
111. Trzonkowski P., Bieniaszewska M., JuŚcińska J., Dobyszuk A., Krzystyniak A., Marek N., et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- Tregulatory cells. Clin Immunol 2009, 133:22-26.
112. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GvHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
113. Ekberg H., Bernasconi C., Tedesco-Silva H., Vítko S., Hugo C., Demirbas A., et al. Calcineurin inhibitor minimization in the symphony study: observational results 3 years after transplantation. Am J Transplant 2009, 9:1876-1885.
114. Newell K.A., Asare A., Kirk A.D., Gisler T.D., Bourcier K., Suthanthiran M., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010, 120:1836-1847.
115. Sagoo P., Perucha E., Sawitzki B., Tomiuk S., Stephens D.A., Miqueu P., et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010, 120:1848-1861.
116. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
117. Trenado A., Charlotte F., Fisson S., Yagello M., Klatzmann D., Salomon B.L., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003, 112:1688-1696.
118. Jones S.C., Murphy G.F., Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003, 9:243-256.
119. Nguyen V.H., Shashidhar S., Chang D.S., Ho L., Kambham N., Bachmann M., et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008, 111:945-953.
120. Bushell A., Jones E., Gallimore A., Wood K. The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol 2005, 174:3290-3297.
121. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
122. Lal G., Zhang N., van der Touw W., Ding Y., Ju W., Bottinger E.P., et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009, 182:259-273.
123. Li L., Kim J., Boussiotis V.A. IL-1beta-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol 2010, 185:4148-4153.
124. Oldenhove G., Bouladoux N., Wohlfert E.A., Hall J.A., Chou D., Dos Santos L., et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.
125. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13:423-431.
126. Yang X.O., Nurieva R., Martinez G.J., Kang H.S., Chung Y., Pappu B.P., et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008, 29:44-56.
127. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009, 106:1903-1908.
128. Rubtsov Y.P., Niec R.E., Josefowicz S., Li L., Darce J., Mathis D., et al. Stability of the regulatory T cell lineage in vivo. Science 2010, 329:1667-1671.
129. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat Rev Immunol 2009, 9:83-89.
130. Sharma M.D., Hou D.Y., Baban B., Koni P.A., He Y., Chandler P.R., et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010, 33:942-954.
131. Tsuji M., Komatsu N., Kawamoto S., Suzuki K., Kanagawa O., Honjo T., et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 2009, 323:1488-1492.
132. Vendetti S., Davidson T.S., Veglia F., Riccomi A., Negri D.R., Lindstedt R., et al. Polyclonal Treg cells enhance the activity of a mucosal adjuvant. Immunol Cell Biol 2010, 88:698-706.
133. Vokaer B., Van Rompaey N., Lemaitre P.H., Lhomme F., Kubjak C., Benghiat F.S., et al. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 2010, 185:3417-3425.
134. Wang Y., Souabni A., Flavell R.A., Wan Y.Y. An intrinsic mechanism predisposes Foxp3-expressing regulatory T cells to Th2 conversion in vivo. J Immunol 2010, 185:5983-5992.
135. Sato T., Neschadim A., Konrad M., Fowler D.H., Lavie A., Medin J.A. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007, 15:962-970.
136. Guillot-Delost M., Cherai M., Hamel Y., Rosenzwajg M., Baillou C., Simonin G., et al. Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med 2008, 10:834-846.
137. Ciceri F., Bonini C., Stanghellini M.T., Bondanza A., Traversari C., Salomoni M., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009, 10:489-500.
138. Demirkiran A., Baan C.C., Kok A., Metselaar H.J., Tilanus H.W., van der Laan L.J. Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation 2007, 83:819-823.
139. Naesens M., Sarwal M.M. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010, 6:614-628.
140. Brouard S., Mansfield E., Braud C., Li L., Giral M., Hsieh S.C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007, 104:15448-15453.
141. Martinez-Llordella M., Lozano J.J., Puig-Pey I., Orlando G., Tisone G., Lerut J., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118:2845-2857.
142. Miqueu P., Degauque N., Guillet M., Giral M., Ruiz C., Pallier A., et al. Analysis of the peripheral T-cell repertoire in kidney transplant patients. Eur J Immunol 2010, 40:3280-3290.